Antiretroviral News and Research

RSS

FDA gives tentative approval to new generic AIDS drug

The Food and Drug Administration (FDA) today announced the tentative approval of generic abacavir sulfate tablets manufactured by Aurobindo Pharma LTD. of Hyderabad, India.

18 May 2006

Important insights into how cells regulate certain growth-proteins

Researchers here have discovered a new mechanism used by cells - and manipulated by retroviruses - to control the making of certain essential proteins, including some involved in cancer.

8 May 2006

New study describes molecular basis of NeuroAIDS

Using multi-disciplinary analysis that included cognitive, neurophysiologic, virologic, and molecular techniques, the team found both a low-level viral infection in the brain and immune cells that had infiltrated the brain in order to protect against the virus.

3 May 2006

Outcome of patients with hepatitis B and HIV infections referred for liver transplantation

A new study on HIV patients who also had Hepatitis B virus (HBV) found that better outcomes are possible if they are referred early for transplant and treated with a combination of drugs for HBV. It is essential to monitor the HBV status of these patients, however, in order to control the emergence of drug-resistant HBV infection.

3 May 2006

'Resonance' may be the reason for virologic failure in STI drug therapy

Researchers have been puzzled over why HIV-positive patients who have periodic, built in interruptions in their drug therapy reach a point where the therapy no longer reduces their viral loads, even in the absence of any evidence of acquired drug resistance.

25 Apr 2006

Primagen awarded U.S. patent for using mitochondrial DNA quantification as biomarker

Primagen Holding BV has announced that the U.S. Patent and Trademark Office has granted a patent for its Mitox mitochondrial DNA quantification technology as biomarkers for efficacy and adverse events of treatment.

19 Apr 2006

Cognitive impairment in people with AIDS exists in two forms

The researchers say their findings indicate there probably are two separate mechanisms that can cause cognitive impairment in people with AIDS.

10 Apr 2006

Facial injections of polylactic acid may help improve loss of fat in the face associated with HIV infection

Facial injections of polylactic acid, a synthetic biodegradable polymer, may help improve the debilitating facial lipoatrophy (loss of fat in the face) associated with HIV infection and its treatment, according to an article in the March issue of Archives of Dermatology.

21 Mar 2006

Cells have a natural defense against HIV

Scientists here have discovered a previously unknown mechanism that cells use to fight off the human immunodeficiency virus (HIV), the cause of AIDS.

14 Mar 2006

Antiretroviral therapy (ART) drugs unlikely to stop HIV spread

Researchers believe antiretroviral therapy (ART) will not be effective in stopping HIV epidemics even if it is made universally available in poorer countries, and that widespread use could even lead to an increase in the numbers infected with HIV.

14 Mar 2006

Completely novel approach to fighting HIV infections

For more than a year, researchers watched patiently as a few computer-simulated HIV protease molecules squirmed into more than 15,000 slightly different shapes. In real time, this contortion takes only a fraction of a second.

13 Mar 2006

Antiretroviral therapy (ART) should be strongly considered in the management of infants infected with HIV

Antiretroviral therapy (ART) for infants born with HIV infection may be most effective when given in their first five months of life, according to a study published in the April 1 issue of The Journal of Infectious Diseases.

9 Mar 2006

Schering-Plough provides update on phase II study of Vicriviroc

Schering-Plough Corporation has provided an update on vicriviroc, its investigational CCR5 receptor antagonist, currently being evaluated by the NIH-sponsored Adult AIDS Clinical Trials Group (ACTG) in an ongoing Phase II clinical study of 118 U.S. treatment-experienced HIV patients.

6 Mar 2006

The incidence, distribution, and control of tuberculosis

A reduction in tuberculosis (TB) incidence, prevalence and death rate can be achieved by 2015 in most parts of the world, with the greatest challenges occurring in Africa and Eastern Europe, according to a projection by the Stop TB Department of the World Health Organization.

1 Mar 2006

HAART is very cost-effective

New research shows that highly active antiretroviral therapy (HAART) is very cost-effective, despite the high price tag. However, the study also shows that reimbursement to physicians treating patients with HIV is critically low, threatening patients' access to care.

1 Mar 2006